DcR2/TRAIL R4 Proteins, Antibodies, cDNA Clones, ELISA Kits Research Reagents

All DcR2/TRAIL R4 reagents are produced in house and quality controlled, including 13 DcR2/TRAIL R4 Antibody, 1 DcR2/TRAIL R4 ELISA, 26 DcR2/TRAIL R4 Gene, 1 DcR2/TRAIL R4 IP Kit, 5 DcR2/TRAIL R4 Lysate, 5 DcR2/TRAIL R4 Protein, 1 DcR2/TRAIL R4 qPCR. All DcR2/TRAIL R4 reagents are ready to use.

All DcR2/TRAIL R4 Reagents

DcR2/TRAIL R4 Protein (5)

    DcR2/TRAIL R4 Antibody (13)

      DcR2/TRAIL R4 ELISA キット(すぐに使用できます)& ELISA抗体ペアセット(すぐに使用できません)(1)

      DcR2/TRAIL R4 cDNA Clone (26)


      クローニングベクター cDNA 製品

      In lentiviral vector


      クローニングベクター cDNA 製品

      In lentiviral vector

      DcR2/TRAIL R4 qPCR Primer (1)

      DcR2/TRAIL R4 Lysate (5)

        DcR2/TRAIL R4 の背景知識

        Tumor necrosis factor receptor superfamily member 1D (TNFRSF1D), also known as TNF-related apoptosis-inducing ligand receptor 4 (TRAIL R4), CD264, and Decoy receptor 2, is a member of the TNF-receptor superfamily. This receptor contains an extracellular TRAIL-binding domain, a transmembrane domain, and a truncated cytoplamic death domain. This receptor does not induce apoptosis, and has been shown to play an inhibitory role in TRAIL-induced cell apoptosis. TRAIL R4/CD264/TNFRSF1D is widely expressed, in particular in fetal kidney, lung and liver, and in adult testis and liver. TRAIL R4/CD264/TNFRSF1D is also expressed in peripheral blood leukocytes, colon and small intestine, ovary, prostate, thymus, spleen, pancreas, kidney, lung, placenta and heart. The signaling capacity of TRAIL R4 is similar to that of TRAIL R1 and TRAIL R2 with respect to NF-κB activation, but differs in its inability to induce apoptosis. TRAIL R4 retains a C-terminal element containing one third of a consensus death domain motif. Transient overexpression of TRAIL R4 in cells normally sensitive to TRAIL-mediated killing confers complete protection, suggesting that one function of TRAIL R4 may be inhibition of TRAIL cytotoxicity.

        DcR2/TRAIL R4 の参考文献

        • Degli-Esposti MA, et al. (1997) The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity. 7(6): 813-20.
        • Meng RD, et al. (2000) The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis. Mol Ther. 1(2): 130-44.
        • Bouralexis S, et al. (2003) Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy. Br J Cancer. 89(1): 206-14.

        Note: Flag® is a registered trademark of Sigma Aldrich Biotechnology LP. It is used here for informational purposes only.